Why Valeant Pharmaceuticals (VRX) Stock Is Down

NEW YORK (TheStreet) -- Shares of Valeant Pharmaceuticals Int'l (VRX) are down -1.27% to $129.50 after it was reported that Allergan, Inc. (AGN) rejected Valeant's unsolicited takeover proposal, saying the offer "substantially undervalues" the maker of the Botox wrinkle treatment, Bloomberg reports.

Allergan's stock is down -1.12% to $159.50

The bid valued Allergan at $45.7 billion in cash and stock when it was announced.

Must Read: Warren Buffett's 10 Favorite Growth Stocks

It creates "significant risks and uncertainties," Alllergan said as the company expects earnings per share to increase 20% to 25% next year, with double-digit revenue growth.

TheStreet Ratings team rates VALEANT PHARMACEUTICALS INTL as a Hold with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation:

"We rate VALEANT PHARMACEUTICALS INTL (VRX) a HOLD. The primary factors that have impacted our rating are mixed some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

If you liked this article you might like

ADP Is Morphing Into the IBM Blob: Bill Ackman

Follow the Crucial '$20 Level Rule' When Trading Stocks

$20 Should Be Your Cutoff Point

Short the Stocks That Fall Below $20

One of the Most Recognized Hedge Fund Managers Has Had a Terrible Year